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a b s t r a c t
Porcine circovirus type 2 (PCV2) vaccination has been effective in protecting pigs from clinical disease
and today is used extensively. Recent studies in vaccinated populations indicate a major PCV2 genotype
shift from the predominant PCV2 genotype 2b towards 2d. The aims of this study were to determine the
ability of the commercial inactivated PCV2a vaccine Circovac to protect pigs against experimental chal-
lenge with a 2013 PCV2d strain and prevent transmission. Thirty-eight pigs were randomly divided into
four groups with 9–10 pigs per group: NEG (sham-vaccinated, sham-challenged), VAC (PCV2a-
vaccinated, sham-challenged), VAC + CHAL (PCV2a-vaccinated and PCV2d-challenged), and CHAL
(sham-vaccinated, PCV2d-challenged). Vaccination was done at 3 weeks of age using Circovac according
to label instructions. The CHAL and VAC + CHAL groups were challenged with PCV2d at 7 weeks of age
and all pigs were necropsied 21 days post-challenge (dpc). The VAC-CHAL pigs seroconverted to PCV2
by 21 days post vaccination (dpv). At PCV2d challenge on 28 dpv, 3/9 VAC and 1/9 VAC + CHAL pigs were
seropositive. NEG pigs remained seronegative for the duration of the study. Vaccination significantly
reduced PCV2d viremia (VAC + CHAL) at dpc 14 and 21, PCV2d fecal shedding at dpc 14 and 21 and
PCV2d nasal shedding at dpc 7, 14 and 21 compared to CHAL pigs. Vaccination significantly reduced mean
PCV2 antigen load in lymph nodes in VAC + CHAL pigs compared to CHAL pigs. When pooled serum or
feces collected from VAC + CHAL and CHAL pigs at dpc 21 were used to expose single-housed PCV2 naïve
pigs, a pooled fecal sample from CHAL pigs contained infectious PCV2 whereas this was not the case for
VAC + CHAL pigs suggesting reduction of PCV2d transmission by vaccination. Under the study conditions,
the PCV2a-based vaccine was effective in reducing PCV2d viremia, tissue loads, shedding and transmis-
sion indicating that PCV2a vaccination should be effective in PCV2d-infected herds.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Porcine circovirus type 2 (PCV2) is a small, non-enveloped,
circular-arranged, single-stranded DNA virus that belongs to the
Circoviridae family [1]. PCV2 is ubiquitous and very resistant to dis-
infection [2] and most pigs get exposed to PCV2 during their life. In
growing pigs, PCV2-infection can be associated with a variety of
clinical manifestations commonly summarized as PCV2 associated
disease (PCVAD) including systemic illness, enteritis and pneumo-
nia [3]. Porcine dermatitis and nephropathy syndrome (PDNS) has
also been linked to PCVAD [4,5], although definitive experimental
proof is still lacking. In addition to PCVAD, PCV2 infection can
result in subclinical disease for extended periods of time, which
can have a varying impact on pork production [6,7]. Non-specific
clinical signs including reduced weight gain associated with sub-
clinical PCV2 infection are thought to occur due to the effect of
PCV2 on the immune system [8].
PCV2 can be classified in five different genotypes including
PCV2a, PCV2b, PCV2c, PCV2d and PCV2e of which PCV2a is the old-
est [9,10]. PCV2c has only been identified in archived pig tissues
http://dx.doi.org/10.1016/j.vaccine.2016.11.085
0264-410X/ 2016 The Author(s). Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author at: The Roslin Institute and The Royal (Dick) School of
Veterinary Studies, University of Edinburgh, Midlothian, Scotland, UK.
E-mail address: Tanja.Opriessnig@roslin.ed.ac.uk (T. Opriessnig).
Vaccine xxx (2016) xxx–xxx
Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc ine
Please cite this article in press as: Opriessnig T et al. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding
and prevents PCV2d transmission to naïve pigs under experimental conditions. Vaccine (2016), http://dx.doi.org/10.1016/j.vaccine.2016.11.085
from Denmark [11] and a recent feral pig sample from Brazil [12]
and is considered of minor importance. Around 2003 a major
genotype shift occurred from PCV2a to PCV2b [11]. Severe PCV2
epidemics linked to PCV2b introduction occurred in North America
during 2005/2006 [13] and subsequently led to introduction and
large scale usage of PCV2 vaccines in pigs. Today PCV2 vaccination
has become a standard management tool in most pig producing
areas [14]. Supported by numerous field and experimental trials,
PCV2 vaccination has been proven to reduce PCV2 infection, vire-
mia and lesions and increases average daily weight gain (ADG)
compared to non-vaccinated pigs [14]. Development of most com-
mercial PCV2 vaccines occurred between 1999 and 2005 when lit-
tle information on PCV2 genotypes was available and PCV2a was
the predominant PCV2 strain at the time. Therefore all major
PCV2 vaccines available to date are based on PCV2a [3]. Neverthe-
less, PCV2a vaccines have been shown to protect pigs against
PCV2b challenge in several independent studies [15,16].
Previously it has been determined that PCV2 has a high muta-
tion rate similar to RNA viruses [17] which may further facilitate
rapid emergence and transmission of unique PCV2 genotypes. Fur-
thermore, pigs are often co-infected with multiple PCV2 strains
[18,19]. Since the beginning of this decade a newly recognized
genotype, PCV2d, emerged in essentially all large pig populations
in North America, South America, Europe and Asia [9,20]. More-
over, several studies indicate that PCV2d is becoming the predom-
inant strain in the global pig population replacing PCV2a and
PCV2b [9,21]. Frequently, the presence of PCV2d has been linked
to PCVAD outbreaks in PCV2-vaccinated herds [22–24] raising con-
cerns that PCV2 vaccines based on PCV2a strains may not provide
sufficient protection against PCV2d strains. The objectives of this
study were to determine the ability of a commercial inactivated
PCV2a vaccine to protect conventional pigs against experimental
challenge and to prevent transmission of a 2013 PCV2d to naïve
contact pigs.
2. Materials and methods
2.1. Ethical statement
The experimental protocol was approved by the Iowa State
University Institutional Animal Care and Use Committee (Approval
number: 11-14-7900-S).
2.2. Animals, housing, and experimental design
Two-week-old, colostrum-fed, crossbred pigs, from a high
health commercial breeding herd free of Mycoplasma hyopneumo-
niae, influenza A virus and porcine reproductive and respiratory
syndrome virus (PRRSV) and with low PCV2 antibody titers in a
portion of the dams and without active PCV2 circulation as evi-
denced by regular PCV2 PCR testing on pooled serum samples,
were purchased for this study. For the main study 38 pigs were
randomly assigned to one of four rooms and groups with 9–10 pigs
in each group (Table 1). For the contact exposure part of the study,
14 age-matched contact pigs were group-housed in a different
room until 7 weeks of age. At that point the contact pigs were
moved to individual rooms and were single housed (Fig. 1). Each
room contained one pen with one nipple drinker and one self-
feeder. All groups were fed ad libitum with a balanced, age-
appropriate, pelleted feed ration. The experimental design and
sample collections are summarized in Fig. 1. Blood was collected
in serum separator tubes (BD Vacutainer SST, REF 367088; Fisher
Scientific, Pittsburgh, PA, USA), centrifuged at 3000g for 10 min
at 4 C, and the serum was stored at 80 C until testing. Nasal
and rectal swabs were collected using polyester swabs and were
stored in 5 ml plastic tubes containing 1 ml of sterile saline solu-
tion at 80 C until testing.
2.3. Vaccination
At 3 weeks of age (dpv 0 or dpc 28), the VAC and VAC + CHAL
pigs were vaccinated intramuscularly in the left neck with 0.5 ml
of Circovac (Merial; Lot No. L404456) as recommended by the
manufacturer (Table 1). Similarly, the CHAL and NEG pigs were
sham-vaccinated intramuscularly in the left neck with 0.5 ml
saline.
2.4. Challenge
PCV2d isolate JX535296 [22,25] was grown to a final titer of
104.33 50% tissue culture infectious dose (TCID50) per ml. At
7 weeks of age (dpv 28 or dpc 0), CHAL and VAC-CHAL pigs
(Table 1) received 4.5 ml of the PCV2d challenge virus stock intra-
nasally by slowly dripping 2.25 ml in each nostril. Pigs in the VAC
and NEG groups were sham-inoculated with 4.5 ml saline, which
was also given intranasally.
2.5. Contact pig exposure
Two serum pools were generated by combining serum samples
from all VAC-CHAL or all CHAL pigs collected at day post-challenge
(dpc) 21. Once combined, 3 ml of the VAC-CHAL dpc 21 serum pool
were administered to contact pigs 10, 11, 12 (Fig. 1) by the intra-
muscular route at day post-exposure (dpe) 0. Similarly, contact
pigs 4, 5 and 6 received 3 ml of the CHAL dpc serum pool by the
intramuscular route at dpe 0. Fecal material collected on dpc 21
from VAC-CHAL pigs was diluted in phosphate buffered saline
(PBS) and contact pigs 7, 8 and 9 each received 8 ml of fecal sus-
pension by the oral route while 8 ml of fecal suspension collected
on dpc 21 from CHAL pigs were administered orally to contact pigs
1, 2 and 3. Contact pigs 13 and 14 served as non-infected negative
controls (Fig. 1).
2.6. Average daily weight gain and clinical observations
All pigs in the main study were weighed at 3 weeks of age
(dpv 0 or dpc 28), at 7 weeks of age (dpv 28 or dpc 0) and at
10 weeks of age (dpc 21; Fig. 1). The average daily weight gain
Table 1
Experimental groups, treatments at different days post PCV2d challenge (dpc) and average daily weight gain (ADG).
Group designation Number of pigs Vaccination Challenge ADGa
dpc 28 dpc 0 Vaccination to challenge Challenge to necropsy
NEG 10 Saline Saline 463.3 ± 25.2 795.4 ± 40.4
VAC 9 Circovac Saline 351.6 ± 29.0 744.7 ± 46.6
VAC + CHAL 9 Circovac PCV2d 426.5 ± 21.6 774.0 ± 46.6
CHAL 10 Saline PCV2d 412.7 ± 26.0 726.0 ± 49.5
a Data presented as group mean ADG in grams ± SEM.
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was calculated before (dpv 0 to dpv 28) and after PCV2d challenge
(dpc 0–21). After PCV2d challenge, all animals were examined
daily for signs of illness such as lethargy, respiratory disease, inap-
petence and lameness.
2.7. Serology
Serum samples collected at dpc 28, 0, 7, 14, and 21 for the
main study and serum samples collected at dpe 0, 7 and 14 for con-
tact pigs were tested for the presence of anti-PCV2 IgG antibodies
by a commercial blocking ELISA (SERELISA PCV2 Ab Mono Block-
ing; Zoetis). Samples titers were calculated based on single dilu-
tions using the calculation sheet supplied by the manufacturer.
2.8. DNA extraction, detection, quantification and PCV2d confirmation
Total nucleic acids were extracted from all serum samples using
the MagMaxTM Pathogen RNA Kit (Applied Biosystems, Life Tech-
nologies, Carlsbad, CA, USA) on an automated nucleic acid extrac-
tion system (Thermo Scientific Kingfisher Flex, Thermo Fisher
Scientific, Pittsburgh, PA, USA) according to the instructions of
the manufacturer. All DNA extracts were tested for the presence
of PCV2 DNA by a quantitative real-time PCR assay targeting a con-
served region in ORF1 as described previously [25,26]. Samples
were considered negative when no signal was observed within
the 40 amplification cycles. A differential real-time PCR assay tar-
geting open-reading frame 2 (ORF2) and capable of detecting and
differentiating PCV2a, PCV2b and PCV2d was done on all PCV2
PCR-positive pigs at dpc 21 [27]. The differential PCR assay does
not react with PCV2c due to a primer mismatch. Selected PCV2
PCR-positive samples were sequenced by using a conventional
PCR covering the entire ORF2 as described previously [18] at the
Iowa State University DNA Facility, Ames, IA, USA.
2.9. Necropsy
At dpc 21 when the pigs in the main study were 10 weeks old,
they were euthanized by intravenous pentobarbital sodium over-
dose (Fatal Plus, Vortech Pharmaceuticals, LTD, Dearborn, MI,
USA) and necropsied. Contact pigs were necropsied at 14 dpe when
they were 12 weeks old. As part of a routine necropsy protocol, the
extent of macroscopic lung lesions ranging from 0% to 100% was
estimated and blindly scored as described previously [28]. The size
of superficial inguinal lymph nodes was scored as described previ-
ously [29]. Sections of lymph nodes (superficial inguinal, external
iliac, mediastinal, tracheobronchial, and mesenteric), tonsil, spleen,
kidney, liver, and small intestines (ileum) were collected at
necropsy, fixed in 10% neutral-buffered formalin, and routinely
processed for histological examination.
2.10. Histopathology, immunohistochemistry, and overall lymphoid
lesion score
Microscopic lesions were evaluated by a veterinary pathologist
blinded to the treatment groups. Lymph nodes, spleen, and tonsil
were evaluated for presence and degree of lymphoid depletion
and granulomatous replacement of follicles ranging from 0 (nor-
mal) to 3 (severe) [30]. Lung sections were scored for the presence
and severity of interstitial pneumonia, ranging from 0 (normal) to
6 (severe diffuse) [28]. Sections of ileum, liver and kidney were
evaluated for the presence of granulomatous inflammation and
scored from 0 (none) to 3 (severe). Immunohistochemistry (IHC)
for detection of PCV2 antigen was performed on formalin-fixed
and paraffin-embedded sections of lungs, lymph nodes, tonsil,
and spleen from all pigs using a rabbit PCV2 polyclonal antiserum
[31]. PCV2 antigen scoring was done by a veterinary pathologist
blinded to the treatment status. Scores ranged from 0 (no signal)
to 3 (more than 50% of lymphoid follicles contained cells with
PCV2 antigen staining) [30]. The overall lymphoid lesion score
was calculated as described [30]. In brief, a combined scoring sys-
tem for each lymphoid tissue that ranged from 0 to 9 (lymphoid
depletion score 0–3; granulomatous inflammation score 0–3;
PCV2 IHC score 0–3) was used.
2.11. Statistical analysis
For data analysis, JMP software version 11.0.0 (SAS Institute,
Cary, NC, USA) was used. Summary statistics were calculated for
Fig. 1. Experimental design and sample collections for the main study (A) and for the contact exposure (B). For the contact exposure, feces and blood collected from the CHAL
room or the VAC + CHAL room at dpc 21 were pooled by room and administered by the oral (feces) or intramuscular (serum) route to PCV2 naïve contact pigs which were
single housed (one pig per room) in a different building.
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all the groups to assess the overall quality of the data set including
normality. Statistical analysis of the data was performed by one-
way analysis of variance (ANOVA) for continuous data. A P-value
of less than 0.05 was set as the statistically significant level. Pair-
wise test using Tukey’s adjustment was subsequently performed
to determine significant group differences. Real-time PCR results
(copies per ml of serum) were log10 transformed prior to statistical
analysis. Statistical analysis for continuous data over time was
done by repeated measures multiple analysis of variance (MAN-
OVA). The serology response was assessed between the VAC and
VAC + CHAL groups and the PCR results were compared between
VAC + CHAL and CHAL groups to determine a time-by-group inter-
action. Non-repeated nominal data were assessed using a non-
parametric Kruskal-Wallis one-way ANOVA, and if significant,
pairwise Wilcoxon tests were used to evaluate differences among
groups. Differences in incidence were evaluated by using the chi-
square test. Percent reduction for the amount of PCV2 DNA was
determined as follows: 100  [(100 mean log10 genomic
copies/ml in the vaccinated group)  (mean log10 genomic
copies/ml in positive control animals)].
3. Results
3.1. Clinical observation and average daily weight gain (ADG)
No remarkable clinical signs were noted. The ADG is summa-
rized in Table 1. There were no significant differences among
groups.
3.2. Anti-PCV2 antibody levels
At dpv 0, dpv 7 and dpv 14 all pigs were negative for PCV2-
specific antibodies. One VAC + CHAL pig seroconverted to PCV2
by dpv 21. At dpv 28/dpc 0, PCV2 specific antibodies were detected
in 3/9 VAC pigs and 4/9 VAC + CHAL pigs. The group mean log PCV2
ELISA titers from dpc 0 through dpc 21 are summarized in Fig. 2.
While the PCV2-antibody titers in VAC + CHAL pigs continued to
increase after challenge, titers in non-challenged VAC pigs started
to decrease (Fig. 2); the time by group interaction was not signifi-
cant (F[3,32] = 0.5914; P = 0.38; g2 = 0.64).
3.3. Prevalence and amount of PCV2 DNA in serum, rectal swabs and
nasal swabs
At arrival at the research facility all pigs were negative for PCV2
DNA and all pigs remained PCV2 DNA negative until challenge.
There was a significant time by group interaction (F[1,18]
= 4.5882; P = 0.04; g2 = 0.53) for PCV2 viremia between the two
challenged groups (Fig. 3). After PCV2d challenge, 8/10 CHAL pigs
were viremic at dpc 7 and all 10 pigs in this group were viremic
at dpc 14 and 21. For the VAC + CHAL pigs, 7/9 were viremic at
dpc 7, 6/9 were viremic at dpc 14 and 6/9 were viremic at dpc
21. Group mean genomic copies in serum were significantly
(P < 0.05) lower for VAC + CHAL pigs compared to CHAL pigs at
dpc 14 and 21 (Fig. 3) and by 21 dpc, VAC + CHAL pigs had a
63.8% reduction for the amount of PCV2 DNA in serum compared
to the CHAL pigs. In addition, there was a significant time by group
interaction (F[1,22] = 5.4405; P = 0.02; g2 = 0.65) for fecal shed-
ding between the two challenged groups. VAC + CHAL pigs had sig-
nificantly (P < 0.05) reduced PCV2d fecal shedding on dpc 14 and
dpc 21 compared to CHAL pigs with a 41.9% reduction in PCV2d
amount in VAC + CHAL pigs by dpc 21 compared to CHAL pigs.
For PCV2 detection in nasal swabs there was a significant time
by group interaction (F[2,28] = 4.3870; P = 0.03; g2 = 0.82). By
dpc 21 nasal shedding was reduced by 59.2% in VAC + CHAL pigs
compared to CHAL pigs (Fig. 3). The PCV2 present in the pigs was
confirmed to be PCV2d by PCV2 differential real-time PCR on PCR
positive samples collected on dpc 21.
3.4. Macroscopic lesions
At necropsy at dpc 21, the lymph nodes appeared mild-to-
moderately enlarged in all pigs regardless of treatment status.
One VAC + CHAL pig had multiple 0.5–1 cm round-to-oval dark
red purple skin lesions in the perineal region, petechial hemor-
rhage in the cortex area of both kidneys which were tan and
Fig. 2. Anti-PCV2 IgG response. Pigs were vaccinated against PCV2 at 3 weeks of age (dpv 0 or dpc 28) and challenged with PCV2d at 7 weeks of age (dpv 28 or dpc 0). Data
presented as mean group log10 ELISA titer ± SEM. Group means include positive and negative pigs. Significantly different values for a dpc are indicated by different
superscripts. The significance level was set to P > 0.05.
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slightly enlarged. This pig also had severe chronic gastric ulcera-
tion. There were no remarkable macroscopic lesions in any of the
other pigs.
3.5. Microscopic lesions and PCV2 antigen in tissues
Microscopic lesions are summarized in Table 2. Microscopic
lesions in lymphoid tissues were absent in NEG and VAC pigs. In
selected PCV2d-infected pigs regardless of vaccination status, there
was mild-to-severe lymphoid depletion and histiocytic replace-
ment of follicles. PCV2 antigen in lymph nodes was detected in sig-
nificantly (P < 0.05) more CHAL pigs (6/10) compared to VAC
+ CHAL pigs (1/9) in lymphoid tissues and the amount of PCV2
antigen was significantly (P < 0.05) reduced in vaccinated pigs
(Table 2). The distribution of overall lymphoid depletion score cat-
egory distribution was 3/9 normal, 5/9 mild and 1/9 severe for
VAC + CHAL pigs; and 2/10 normal, 5/10 mild, 2/10 moderate and
1/10 severe for CHAL pigs. Individual pigs in all groups regardless
of vaccination or infection status had focal-to-multifocal intersti-
tial pneumonia characterized by increased numbers of lympho-
cytes and macrophages in the alveolar septum and mild type 2
pneumocyte hypertrophy and hyperplasia (score 1). Scores of 2
or 3 were only seen in CHAL and VAC + CHAL pigs. Several
PCV2d-infected pigs (1/9 VAC + CHAL pigs and 4/10 CHAL pigs)
had PCV2d antigen in the cytoplasm of epithelium cells lining large
bronchi and bronchioles in lung tissues (Table 2). The VAC + CHAL
pig that had macroscopic lesions consistent with porcine dermati-
tis and nephropathy syndrome (PDNS) had severe lymphoid deple-
tion and histioctytic replacement of follicles, severe diffuse
lymphohistiocytic hepatitis and tubulointerstitial glomeru-
lonephritis with multifocal necrosis of intraglomerular cells and
extension of Bowman’s spaces by a homogenous eosinophilic
material. PCV2 antigen in this pig was identified in low levels in
lymph nodes (score 1) but was not present in renal tissues or liver.
3.6. Contact pigs
Contact pigs 1 and 2 exposed to dpc 21 fecal material from the
CHAL pigs (Fig. 1) were PCV2 viremic at 14 dpc and also shed PCV2
DNA in nasal and fecal excretions (log10 PCV2 genomic copy range
from 0.88 to 2.56). PCV2 positive PCR products were sequenced
and the presence of the PCV2d strain used to inoculate the pigs
in the main study was confirmed (data not shown). PCV2 DNA
was not detected in any of the other pigs in samples collected at
dpe 0, 7 or 14. None of the contact pigs had seroconverted to
PCV2 at study termination.
4. Discussion
With the emergence of PCV2d strains in most major swine pro-
ducing areas across the globe [9], there are concerns over the effi-
cacy of current PCV2a-based commercial vaccines. Previously it
has been shown that selected commercial subunit or chimeric
PCV2 vaccines can protect pigs against PCV2d challenge [27,32].
To investigate the ability of Circovac to protect against PCV2d
challenge, pigs were vaccinated at 3 weeks of age and challenged
at 7 weeks of age with PCV2d under experimental conditions. This
model is representative of what is occurring in the U.S. field where
pigs commonly are vaccinated at weaning at 3 weeks of age and
get exposed to PCV2 during the nursery period.
The vaccine used in this study, Circovac, is an inactivated vac-
cine based on a PCV2a strain isolated in the 1990s and is one of the
Fig. 3. PCV2 viremia, fecal shedding and nasal shedding. Pigs were vaccinated against PCV2 at 3 weeks of age (dpv 0 or dpc28) and challenged with PCV2d at 7 weeks of age
(dpv 28 or dpc 0). Data presented as mean group log10 PCV2 genomic copies per ml serum samples, rectal swabs or nasal swabs ± SEM. Group means include positive and
negative pigs (considered as 0). Significantly different values for a sample type and dpc are indicated by different superscripts. The significance level was set to P > 0.05.
T. Opriessnig et al. / Vaccine xxx (2016) xxx–xxx 5
Please cite this article in press as: Opriessnig T et al. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding
and prevents PCV2d transmission to naïve pigs under experimental conditions. Vaccine (2016), http://dx.doi.org/10.1016/j.vaccine.2016.11.085
PCV2 vaccines that has been on the market the longest. Initially
this vaccine was developed for usage in adult females in the breed-
ing herd to passively protect suckling and nursery pigs. In 2011,
Circovac was also licensed for use in piglets using the same vac-
cine preparation but at a lower dose compared to sows (0.5 ml ver-
sus 2 ml). In field and experimental studies, Circovac has been
shown to be effective at protecting pigs against the effects of
PCV2a and PCV2b challenges when used in sows or piglets
[7,33,34].
In the present study, at the time of challenge 38.9% of the VAC
+ CHAL pigs had detectable anti-PCV2 IgG antibody titers which
continued to rise after PCV2d challenge and were significantly
higher compared to CHAL or VAC pigs at dpc 21. While a detectable
antibody response to PCV2 vaccination is a good predictor for suc-
cessful vaccine administration, it is not necessary to confer protec-
tion to pigs. It has been demonstrated that pigs with no detectable
humoral response after PCV2 vaccination were protected from sub-
sequent challenge likely due to induction of cellular immunity
[35,36]. While in this study 4/9 VAC + CHAL pigs had detectable
antibody titers at challenge, 8/9 VAC + CHAL were protected from
subsequent PCV2d challenge and had significantly reduced PCV2d
viremia and PCV2d nasal and fecal shedding compared to CHAL
pigs indicating that Circovac confers protection against PCV2d.
PCV2d differs from PCV2a by 6.9–9.4% based on amino acids in
ORF2. There are several immunodominant regions in ORF2 and
PCV2d possess 10 unique amino acid changes in these regions
compared to PCV2a strains [9]. Even if one or more of these epi-
topes would not react with PCV2a antibodies, as Circovac is based
on a full PCV2a strain, antibodies against other regions likely are
sufficient to provide protection. In addition, the adjuvant in Circo-
vac, TS6 ImmuneasyTM, may have a critical role in protection espe-
cially if it can enhance cellular immunity. Cellular immunity was
not tested in this study, but in a previous dam vaccination study,
Circovac induced a strong maternally-derived cellular immune
response in the offspring of vaccinated sows [37].
One of the VAC + CHAL pigs developed clinical PDNS during this
study. To our knowledge this is the first report of PDNS in pigs vac-
cinated and experimentally infected with PCV2. It has been sug-
gested that excessive PCV2 antibody titers may trigger the
development of PDNS [38]. In addition, other etiological agents
such as PRRSV and torque teno virus [39] or PCV3 [40] have also
been proposed as triggers or causative agents in PDNS. The
PDNS-affected pig in this study had no detectable PCV2 antibody
titer at challenge and the titer increased towards a low positive
level over the following weeks. It also has been suggested that
PDNS pigs may have a misdirected, excessive immune response
towards a decoy epitope called CP(169–180) which is located in
ORF2 of PCV2 [41,42]. Tests to detect antibodies against CP(169–
180) were not available. While PDNS in the past often occurred a
few weeks following outbreaks of systemic PCVAD, it appears that
PDNS became rare after large-scale introduction of PCV2 vaccina-
tion. This suggests that PCV2 vaccination prevents development
of PDNS. The reasons why the PCV2 vaccinated pig in this study
developed PDNS remain unknown but could include an elevated
anti-PCV2 IgM response (which was not tested) or failure to appro-
priately vaccinate the pig. Alternatively, the gastric ulceration
could perhaps have acted as a predisposing factor for a septic
event. While PRRSV was not present in the pigs, another un-
recognized co-infecting agent could have contributed to the devel-
opment of PDNS.
PCV2 is ubiquitous, very difficult to remove from a farm and
easily transmissible to naïve pigs [2]. In this study, PCV2 in feces
collected at dpc 21 was transmissible to naïve pigs from non-
vaccinated pigs but not from vaccinated pigs indicating that vacci-
nation reduces PCV2 transmission. This is important considering
that routine cleaning procedures on a farm prior to getting a new
batch of pigs may not always be sufficient to remove PCV2
[43,44] and reduction of virus loads by vaccination could assist
in preventing transmission of PCV2.
5. Conclusions
Under the conditions of this study, PCV2a vaccination reduced
PCV2d viremia, PCV2d tissue loads and PCV2d shedding via nasal
and fecal routes. In addition, PCV2a-vaccinated and PCV2d-
challenged pigs did not transmit PCV2d to naïve contact pigs
whereas non-vaccinated PCV2d infected pigs did. PCV2a vaccina-
tion was effective against PCV2d challenge.
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